Special Issues

New Advances in Oral Diseases and Risk Factors of Oral Inflammation for Systemic Health
Editor: Gaetano Isola

Submission Deadline: 31 December 2023 (Status: Open)

Special Issue Editor

Dr. Gaetano Isola      Email   |   Website
Department of General Surgery and Surgical-Medical Specialties, University of Catania, Catania, Italy
Interests: oral medicine; periodontology; oral diseases; biomaterials; oral biomarkers

Special Issue Information

Dear Colleagues,

It is well recognized that oral disorders are common worldwide and, if untreated, can worsen general health. The most common oral disorders causing tooth loss, dental caries, periodontal disease, lips malignancies and oral cavity are the most prevalent. Early detection and successful treatment of oral problems are now possible due to personalized dentistry. Innovative approaches and methods are in need to either improve our understanding of oral diseases pathobiology or to successfully treat individuals diagnosed with these lesions.

The goal of this Special Issue is to raise the standard of treatment for patients with these illnesses and lesions by focusing on the most recent research and innovations in oral diseases from bench to bedside.

Gaetano Isola
Guest Editor


periodontitis; oral diseases; biomakers; cytotoxic elements; oral microbiome; inflammation; probiotics; metabolic disease

Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://www.biolifesas.org/journalx_brha/authorLogOn.action by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. Submitted manuscripts should be well formatted in good English.

Sort by Default Latest Most read  
Please wait a minute...
  • Select all
  • Review
    Florin Onisor, Andra Piciu, Simion Bran, Alexandru Mester
    Journal of Biological Regulators and Homeostatic Agents. 2023, 37(5): 2339-2343. https://doi.org/10.23812/j.biol.regul.homeost.agents.20233705.230
    Download PDF (56) HTML (0)   Knowledge map   Save

    Background: Oral lichen planus (OLP) is a chronic inflammatory disease associated with T-cell-mediated immunological dysfunction. Hepatitis C virus (HCV) infection has been related to OLP. The aim of this systematic review was to assess the efficiency of direct-acting antivirals (DAA) in patients with HCV on the oral lichen planus.

    Methods: This systematic review was conducted under the recommendations of Cochrane Handbook for Systematic Reviews of Interventions and the PRISMA guidelines. PubMed, Scopus and Web of Science databases were searched up to 30 December 2022. Specific keywords were used to search the electronic databases. Titles and abstracts were firstly screened for eligibility. Then, full-text articles for eligible studies were examined. In the end, studies which respected the inclusion criteria were considered. Risk of bias was assessed according to The Strengthening the Reporting of Observational studies in Epidemiology Statement (STROBE).

    Results: Types of OLP presented were erosive, reticular or mixed. OLP localization was on buccal mucosa (uni/bilateral), sublingual mucosa, tongue, or lower lip. At 24 weeks, most of the patients showed OLP disappearance with no adverse events; only 1 patient developed oral squamous cell carcinoma of the tongue. HCV elimination via DAA therapy improved also OLP present in those patients and reduced the periodontal pathogens.

    Conclusions: The use of DAA in patients with HCV and OLP might be a promising treatment in both diseases without using an adjuvant therapy.